STENOCARE reports 53% revenue growth in Q3-2026 and maintains full-year ambition for positive EBITDA

STENOCARE reported Q3 2026 net sales of DKK 2.935 million, up 53% year over year, and nine-month net sales of DKK 9.935 million, up 125% from the same period in 2025. The company said the results report had not been reviewed by its auditors; the supplied article text cuts off before providing the Q3 EBITDA figure.

Analysis

The key question is whether sales growth is converting into durable cash generation, not whether the growth rate looks strong. The disclosed quarterly revenue base remains small in absolute terms, so modest customer wins or supply changes can produce large percentage swings without yet demonstrating scalable economics. The release is unaudited, and the excerpt omits the EBITDA result; profitability, gross margin, cash flow and working-capital movements therefore remain unverified.

Near term, the market may reward the growth headline, but the 1–3 month catalyst is the complete report and evidence that margin and cash conversion are improving alongside sales. Over 6–18 months, the upside case depends on repeat demand and reliable product access; the counter-risk is that supply, regulatory or reimbursement constraints limit conversion of demand into revenue. Any funding or dilution concern is conditional: check cash runway and operating cash burn before drawing conclusions.

This is not yet a robust fundamental signal. A contrarian risk is that investors extrapolate growth from a small base while underweighting earnings quality and liquidity; conversely, if the omitted figures show improving cash economics, the market may be discounting the operating leverage. The thesis weakens if the full report shows worsening EBITDA or cash burn, or if subsequent sales growth stalls.

Key Decisions for Investors

• No immediate directional trade on the excerpt alone. Avoid chasing the growth headline until the full report establishes EBITDA, gross margin, operating cash flow, cash balance and working-capital trends.
• Treat STENO as a watchlist catalyst rather than a confirmed growth position: reassess after the full report and next sales update. Consider exposure only if revenue growth is accompanied by improving unit economics and a credible cash runway.
• For any position, verify trading liquidity and spreads first; use limited sizing given the small disclosed revenue base and the possibility that reported growth is volatile.
• Falsification signals: a material deterioration in EBITDA or cash conversion in the full report, evidence of constrained product availability, or subsequent sales that fail to sustain growth. A sustained improvement in margins and cash generation would challenge the cautious view.